Johnson & Johnson: A High-Quality Dividend King Facing Furious Headwinds


  • Johnson & Johnson focuses on pharmaceuticals and medical devices after spinning off its consumer-health segment.
  • The company’s solid pipeline of cancer, immunology, and neurology drugs, along with its leading medical device portfolio, offer growth prospects.
  • Johnson & Johnson reported strong Q4 earnings, beating revenue forecasts, and expects continued growth in pharmaceutical sales and revenue in FY24.

White Chess King among lying down black pawns on chessboard


This article was coproduced with Chuck Walston.

With the spinoff of its consumer-health segment, now known as Kenvue (KVUE), Johnson & Johnson (NYSE:JNJ) is now focused on its pharmaceuticals and medical devices businesses. Pharmaceuticals now

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Author's note: Brad Thomas is a Wall Street writer, which means he's not always right with his predictions or recommendations. Since that also applies to his grammar, please excuse any typos you may find. Also, this article is free: written and distributed only to assist in research while providing a forum for second-level thinking.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Sign Up For A FREE 2-Week Trial

Join iREIT® on Alpha today… for more in-depth research on REITs, mREITs, Preferreds, BDCs, MLPs, ETFs, Builders, and Asset Managers. You’ll get more articles throughout the week, and access to our Ratings Tracker with buy/sell recommendations on all the stocks we cover. Plus unlimited access to our multi-year Archive of articles. 

Here are more of the features available to you. And there’s nothing to lose with our FREE 2-week trial. Just click this link.

Graphical user interface, text Description automatically generated

And this offer includes a FREE copy of my new book, REITs for Dummies!

Leave a Reply

Your email address will not be published. Required fields are marked *